Skip to content
Screener

Celldex Therapeutics CLDX Q2 2025 earnings

Reported August 7, 2025 · Before market open

Revenue$730.0KMiss by $453.9K
EPS-$0.85Beat by $0.01
Revenue estimate$1.2M
EPS estimate-$0.86

Next report

Nov 9, 2026 (in 2 months)
Revenue estimate$722.6K
EPS estimate-$1.02

Financials

Q2 2025

Income statement

See full
Revenue$730.0K-70.8%
Operating income-$63.9M-37.9%
Net income-$56.6M-57.9%
EPS (diluted)-$0.85-57.4%

Balance sheet

See full
Cash & equivalents$23.0M-46.1%
Total debt$3.0M+27.1%
Total equity$655.4M-19.4%
Total assets$692.4M-18.1%

Cash flow

See full
Operating cash flow-$44.0M-50.0%
CapEx$728.0K+166%
Free cash flow-$44.7M-51.1%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$1.44B-41.1%
Enterprise value$1.42B-40.9%
P/S248.2×-45.6×

Profitability

See full
Operating margin-4,053.7%+43,311pp
Net margin-3,446.9%+32,833pp
FCF margin-3,254.8%-19,688pp

Returns & leverage

See full
Return on equity-27.2%-0.3pp
Debt / equity0×0.0×
Current ratio19.7×-9.7×

Segments

By product

See full
Grant$723.0K-71.1%
Service$7.0K—

FAQ

When did Celldex Therapeutics report Q2 2025 earnings?
Celldex Therapeutics (CLDX) reported Q2 2025 earnings on August 7, 2025 before market open.
What were Celldex Therapeutics's Q2 2025 revenue and EPS?
Celldex Therapeutics reported revenue of $730.0K and eps of $-0.85 for Q2 2025.
Did Celldex Therapeutics beat estimates in Q2 2025?
Revenue missed the consensus estimate of $1.2M by $453.9K. EPS beat the consensus estimate of $-0.86 by $0.01.
How did Celldex Therapeutics's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 70.8% from $2.5M a year earlier and eps declined 57.4% from $-0.54.
Where can I find Celldex Therapeutics's Q2 2025 SEC filings?
You can read the 8-K earnings release (0001171843-25-005181) and the 10-Q periodic report (0001410578-25-001610) directly on SEC EDGAR. The filing index links above go to sec.gov.